310 related articles for article (PubMed ID: 25278312)
1. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
2. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
3. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
[No Abstract] [Full Text] [Related]
4. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
7. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
8. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
[TBL] [Abstract][Full Text] [Related]
10. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
13. FOLFIRINOX: from the ACCORD study to 2014.
Oikonomopoulos GM; Syrigos KN; Skoura E; Saif MW
JOP; 2014 Mar; 15(2):103-5. PubMed ID: 24618428
[TBL] [Abstract][Full Text] [Related]
14. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
[TBL] [Abstract][Full Text] [Related]
15. Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
Shinagare AB; Ramaiya NH; Bellizzi AM; Mayer RJ
Pancreatology; 2012; 12(1):35-8. PubMed ID: 22487471
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.
Baldini C; Escande A; Bouché O; El Hajbi F; Volet J; Bourgeois V; Renaut Vantroys T; Ploquin A; Desauw C; Hebbar M
Pancreatology; 2017; 17(1):146-149. PubMed ID: 28040425
[TBL] [Abstract][Full Text] [Related]
17. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
[TBL] [Abstract][Full Text] [Related]
18. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
[TBL] [Abstract][Full Text] [Related]
19. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
20. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
Neofytou K; Giakoustidis A; Smyth EC; Cunningham D; Mudan S
J Surg Oncol; 2015 May; 111(6):768-70. PubMed ID: 25556724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
